Suppr超能文献

医学中的植物性、合成性和内源性大麻素。

Plant, synthetic, and endogenous cannabinoids in medicine.

作者信息

Di Marzo Vincenzo, Petrocellis Luciano De

机构信息

Endocannabinoid Research Group, Institutes of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Naples, Italy.

出版信息

Annu Rev Med. 2006;57:553-74. doi: 10.1146/annurev.med.57.011205.135648.

Abstract

Although used for more than 4000 years for recreational and medicinal purposes, Cannabis and its best-known pharmacologically active constituents, the cannabinoids, became a protagonist in medical research only recently. This revival of interest is explained by the finding in the 1990s of the mechanism of action of the main psychotropic cannabinoid, Delta9-tetrahydrocannabinol (THC), which acts through specific membrane receptors, the cannabinoid receptors. The molecular characterization of these receptors allowed the development of synthetic molecules with cannabinoid and noncannabinoid structure and with higher selectivity, metabolic stability, and efficacy than THC, as well as the development of antagonists that have already found pharmaceutical application. The finding of endogenous agonists at these receptors, the endocannabinoids, opened new therapeutic possibilities through the modulation of the activity of cannabinoid receptors by targeting the biochemical mechanisms controlling endocannabinoid tissue levels.

摘要

尽管大麻及其最著名的药理活性成分大麻素用于娱乐和医疗目的已有4000多年历史,但直到最近才成为医学研究的主角。20世纪90年代发现主要精神活性大麻素Δ9-四氢大麻酚(THC)的作用机制是通过特定的膜受体即大麻素受体起作用,这一发现解释了人们对其兴趣的再度兴起。这些受体的分子特征使得能够开发出具有大麻素和非大麻素结构、比THC具有更高选择性、代谢稳定性和功效的合成分子,以及已经在制药领域得到应用的拮抗剂。这些受体的内源性激动剂即内源性大麻素的发现,通过靶向控制内源性大麻素组织水平的生化机制来调节大麻素受体的活性,从而开辟了新的治疗可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验